Blinatumomab for Acute Lymphoblastic Leukemia Relapse After Allogeneic Hematopoietic Stem Cell Transplantation

The outcomes of patients with relapsed/refractory (R/R) acute lymphoblastic leukemia (ALL) following allogeneic hematopoietic stem cell transplantation (alloHSCT) are poor. A retrospective analysis of adults with ALL who relapsed after first alloHSCT and received salvage therapies, including a second HSCT, donor lymphocyte infusion with or without prior chemotherapy, radiation therapy, cytoreductive chemotherapy, mild chemotherapy, or palliative care, showed 1- and 2-year overall survival rates of 17% and 10%, respectively [1].

Source: Biology of Blood and Marrow Transplantation - April 15, 2019 Category: Hematology Authors: Anthony S. Stein, Hagop Kantarjian, Nicola G ökbuget, Ralf Bargou, Mark R. Litzow, Alessandro Rambaldi, Josep-Maria Ribera, Alicia Zhang, Zachary Zimmerman, Gerhard Zugmaier, Max S. Topp Source Type: research